Recurrent Small Cell Lung Carcinoma

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
Laboratory Biomarker AnalysisPhase 21 trial
Active Trials
NCT01876446CompletedEst. Feb 2020
Karyopharm Therapeutics
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT02351505TerminatedEst. Mar 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Karyopharm TherapeuticsSelinexor
Nektar TherapeuticsLaboratory Biomarker Analysis

Clinical Trials (2)

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Start: May 2015Est. completion: Mar 2016
Phase 2Terminated
NCT01876446Nektar TherapeuticsLaboratory Biomarker Analysis

Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer

Start: Aug 2013Est. completion: Feb 2020
Phase 2Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space